The V-Go insulin delivery device used in clinical practice: Patient perception and retrospective analysis of glycemic control

Endocrine Practice

Volumn 18, Issue 5, 2012, Pages 660-667

  Rosenfeld, Cheryl R ^a   Bohannon, Nancy B ^b   Bode, Bruce ^c   Kelman, Adam S ^d   Mintz, Shari N ^a   Schorr, Alan B ^e   Sandberg, Marc I ^f   Nambi, Sridhar ^g   Agarwala, Sumon K ^h   Leichter, Steven B ⁱ   Larrabee, Bart ^j   Shi, Lei ^k   Strange, Poul ^k  

^a North Jersey Endocrine Consultants   (United States)

^b Department of Anesthesia   (United States)

^c ATLANTA DIABETES ASSOCIATES   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e St Mary's Medical Center   (United States)

^f Hunterdon Medical Center   (United States)

^g SAINT BARNABAS MEDICAL CENTER   (United States)

^h Lehigh Valley Physician Group   (United States)

ⁱ Endocrine Consultants   (United States)

^j Valeritas   (United States)

^k Integrated Medical Development   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; PRAMLINTIDE; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL PRACTICE; DIABETES MELLITUS; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN INFUSION; INSULIN TREATMENT; MALE; PATIENT SATISFACTION; TREATMENT DURATION; AGED; MIDDLE AGED; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY;

ADULT; AGED; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84867367735     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11362.OR     Document Type: Article

References (8)

1. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glyce-mic control improving in U.S. adults? Diabetes Care. 2008; 31:81-86.
2. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 dia-betes previously treated with glargine plus oral agents: Pran-dial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008;31:20-25.
3. Petrak F, Stridde E, Leverkus F, Crispin AA, Forst T, Pfützner A. Development and validation of a new measure to evaluate psychological resistance to insulin treatment. Diabetes Care. 2007;30:2199-2204.
4. Roper Global Diabetes Program. GfK Heathcare's Roper US Diabetes Patient Market Study. 2008.
5. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev. 2002; 18(Suppl 1):S14-S20.
6. Kapitza C, Fein S, Heinemann L, Schleusener D, Levesque S, Strange P. Basal-prandial insulin delivery in type 2 diabetes mellitus via the V-Go: A novel continuous subcutaneous infusion device. J Diabetes Sci Technol. 2008; 2:40-46.
7. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18: 361-376.
8. Pickup JC, Renard E. Long-Acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care. 2008;31(Suppl 2):S140-S145.